Sign in to follow this  
Followers 0
Joelf

New Page: Uptravi® (Selexipag) for Pulmonary Hypertension

1 post in this topic

Uptravi® (Selexipag) for Pulmonary Hypertension.  Uptravi® (selexipag) is an oral IP prostacyclin receptor agonist marketed by Actelion Pharmaceuticals US, Inc., which was approved by the US FDA for the treatment of pulmonary arterial hypertension in December 2015. Posted 01/29/2016.

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde

ISN Assistant Webmaster

SD World Webmaster

ISN Sclero Forums Manager

ISN News Manager

ISN Hotline Support Specialist

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites
Sign in to follow this  
Followers 0